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Background: While chronic constipation (CC) clinical trials have focused primarily on bowel 
symptoms (symptoms directly related to bowel movements), abdominal symptoms are also 
prevalent among patients. The United States Food and Drug Administration’s (FDA’s) guidance 
on the use of patient-reported outcome measures to support product approvals or labeling claims 
recommends that endpoints be developed with direct patient input and include all symptoms 
important to patients.
Aim: To identify a comprehensive set of CC symptoms that are important to patients for 
measurement in clinical trials.
Methods: Following a targeted literature review to identify CC symptoms previously reported 
by patients, 28 patient interviews were conducted consistent with the FDA’s guidance on patient-
reported outcomes. Subsequent to open-ended questions eliciting descriptions of all symptoms, 
rating and ranking methods were used to identify those of greatest importance to patients.
Results: All 67 studies reviewed included bowel symptoms; more than half also addressed at 
least one abdominal symptom. Interview participants reported 62 potentially distinct concepts: 
12 bowel symptoms; 21 abdominal symptoms; and 29 additional symptoms/impacts. Patients’ 
descriptions revealed that many symptom terms were highly related and/or could be considered 
secondary to CC. The rating and ranking task results suggest that both bowel (for example, 
stool frequency and consistency) and abdominal symptoms (for example, bloating, abdominal 
pain) comprise patients’ most important symptoms. Further, improvements in both bowel and 
abdominal symptoms would constitute an improvement in patients’ CC overall.
Conclusion: Abdominal symptoms in CC patients are equal in relevance to bowel symptoms 
and should also be addressed in clinical trials to fully evaluate treatment benefit.
Keywords: abdominal symptoms, straining, infrequent bowel movements, incomplete bowel 
movements, patient-reported outcomes
Introduction
Chronic constipation (CC) is a significant condition with a prevalence rate estimated 
between 12% and 19% in North America.1–3 CC symptom severity and quality of life 
are negatively correlated.4–6 Wald et al4 demonstrated that the impact of CC on the 
quality of some patients’ lives is similar in magnitude to that of diabetes, hyperten-
sion, depression, and heart disease. CC also has significant economic implications, 
as it can lead to reductions in patients’ productivity and increases in their utilization 
of health care resources.6
Although specific diagnostic criteria are used for clinical trials, the diagnosis of CC 
is subjectively defined in routine clinical practice. Like other functional bowel disor-
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by patients, coupled with the absence of any structural or 
biochemical abnormalities or other medical disorders that 
can cause constipation.7–10 In 1994, the Rome Committee 
published its first set of established diagnostic criteria for 
CC, also known as functional constipation,11 with the intent 
to provide diagnostic consistency and to standardize the CC 
population enrolled in clinical trials. Two further iterations 
of the Rome Criteria have since been published (Rome II12 in 
2000 and Rome III13 in 2006); these criteria are essentially the 
same, with the main difference being the time since diagnosis 
and the duration of active symptoms. The vast majority of 
studies in the medical literature, including those described in 
the current paper (qualitative, survey, and clinical in nature) 
based their inclusion criteria on the Rome II Criteria.
Rome II12 Criteria for diagnosis of CC require two or more 
of the following symptoms for at least 12 weeks (which need 
not be consecutive) in the previous 12 months:
•	 Straining during more than 25% of bowel movements 
(BMs).
•	 Lumpy or hard stools during more than 25% of BMs.
•	 Sensation of incomplete evacuation during more than 
25% of BMs.
•	 Sensation of anorectal obstruction/blockage with more 
than 25% of defecations.
•	 Manual maneuvers to facilitate more than 25% of 
  defecations (for example, digital evacuation, support of 
the pelvic floor).
•	 Fewer than three BMs per week, with each BM occurring 
in the absence of any laxative, suppository, or enema 
usage during the preceding 24 hours.
A Rome II diagnosis of CC also requires that loose stools 
are not present, and there are insufficient criteria for irritable 
bowel syndrome (IBS).12,14
Most commonly, the inclusion criteria and outcome mea-
sures for CC clinical trials have been based solely on stool 
frequency and other bowel symptoms (symptoms directly 
related to BMs), usually those referenced in the Rome Cri-
teria.3,15–18 Whether there are other symptoms of equal or 
greater importance to patients with CC, including abdominal 
symptoms such as discomfort and bloating, has not been 
carefully evaluated by appropriate qualitative methods.
In 2006, the United States Food and Drug Administration 
(FDA) released a guidance document on patient-reported out-
comes (PROs),19 detailing the rigor with which PRO measures 
need to be developed, and the documentation that should be 
submitted if these measures are intended to support product 
approvals or other labeling claims. The FDA’s PRO guidance, 
formally titled Guidance for Industry: Patient-Reported 
Outcome Measures: Use in Medical Product Development 
to Support Labeling Claims, was finalized in December 
2009.20 The PRO guidance recommends that the selection 
of appropriate endpoints for clinical trials be based on direct 
patient input obtained through systematic qualitative research 
involving in-depth individual interviews or focus groups, and 
that all symptoms important to patients are measured.20
The main objectives for the current study were to: 
1) identify a comprehensive set of CC symptoms important 
to patients; and 2) develop items, questions, and response 
options to assess those symptoms that were both unique and 
important to CC patients. The results could then be used to 
inform the selection of PRO endpoints for future clinical 
trials on treatments for CC. While the item development 
process is described very briefly, the focus of this paper is 
on the identification of CC symptoms important to patients 
for assessment in clinical trials.
Methods
literature review
First, a targeted literature review was conducted to identify 
the symptoms reported by patients with CC in previous quali-
tative and observational research, as well as the symptoms 
assessed in clinical trials of new treatments for CC. Inclu-
sion   criteria restricted the search to CC studies published in 
English from January 1993–December 2011, unless a study 
before 1993 was determined to be a key source. Abstracts 
meeting these criteria were selected for review only if 
they included a term describing constipation as a disorder 
(ie, “chronic constipation”; “idiopathic constipation”; or 
  “functional constipation”), as well as one or more of the fol-
lowing terms: “symptoms”; “questionnaire”; “instrument”; 
“scale”; and “patient reported.” From this review, a total of 
67 studies were identified that assessed the patient-reported 
symptoms of CC in the context of qualitative research, ques-
tionnaire validation, patient surveys, randomized controlled 
trials (RCTs), and other interventional studies.
Patient interviews
To supplement and extend the results of the literature review, 
two iterative rounds of qualitative patient interviews were 
conducted and documented in a manner consistent with the 
FDA’s PRO guidance. Each round of interviews was com-
pleted in a different geographic location (round 1 in Raleigh, 
NC, USA and round 2 in Las Vegas, NV , USA) with adults 
who were clinically and demographically similar to patients in 
CC clinical trials. A total of 28 adults completed an   interview: 
15 in round 1 and 13 in round 2. Interview participants were Clinical and Experimental Gastroenterology 2014:7 submit your manuscript | www.dovepress.com
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referred by gastroenterologists and met the Rome II12 Criteria 
for CC, with the exception that reports of manual maneuvers 
(for example, digital manipulation) to facilitate the passage 
of stool and the sensation of anorectal obstruction/blockage 
were not required. Referring clinicians also excluded patients 
who met the Rome II criteria for constipation-predominant 
IBS (IBS-C) or who had a history of any other condition 
that could be associated with dysmotility, constipation, or 
abdominal pain, to ensure that reported symptoms were 
clearly attributable to CC. This study was approved by RTI 
International’s   Institutional Review Board on October 29, 
2008.
To ensure methodological consistency, all 28 interviews 
were conducted by the same pair of experienced interview-
ers using a semistructured interview guide. The interview 
guide was divided into two discrete phases, with each 
phase using slightly different qualitative research methods. 
The first phase of the interview (concept elicitation) was 
dedicated to eliciting a comprehensive set of CC symptoms 
from each interview participant; to understanding the rela-
tionships (if any) between the CC symptoms reported; and 
to understand symptom salience and relative importance. 
The second phase of the interview (cognitive debriefing) 
focused on pretesting items intended for use in upcoming 
CC clinical trials.
At the beginning of the first phase (concept elicitation), 
participants were asked to identify and describe each of their 
CC symptoms. Follow-up questions were posed as needed 
to ensure that each symptom and its relationship to other 
symptoms mentioned by the patient were described in detail; 
however, no symptom was introduced by the interviewers. 
Following this initial open-ended questioning, participants 
were asked whether they experienced any of 22 CC   symptoms 
identified through the literature review, if not mentioned 
spontaneously. This tiered questioning approach facilitated 
an understanding of the relative salience of the CC symptoms 
reported. Specifically, CC symptoms reported during sponta-
neous concept elicitation are likely more important to patients 
than symptoms reported when prompted or probed.
Once a comprehensive set of CC symptoms was identi-
fied for each patient, more structured methods were used to 
understand which CC symptoms and impacts were of greatest 
importance to patients. In round 1, participants were asked to 
identify their most bothersome CC symptoms and to rate the 
importance of bowel and abdominal symptoms commonly 
assessed in CC clinical trials. In round 2, to further elucidate 
the relative importance of identified symptoms, participants 
were asked to identify the five symptoms (among all those 
they experienced) that they would most like to see improved 
with treatment.
During the second phase of each interview (cognitive 
debriefing), participants were asked to provide feedback on 
the specific draft items being tested. Based on analogous work 
conducted by the authors with IBS-C patients, items were 
generated that assessed bowel symptoms (ie, BM frequency, 
incomplete evacuation, straining, and stool consistency), 
as well as abdominal symptoms (ie, pain, discomfort, and 
bloating). During this phase, participants in both rounds of 
interviews were asked to describe, in their own words, what 
each item meant to them, the importance of each item, and the 
appropriateness of the recall period and response options.
Interview data were analyzed using standard qualitative 
analytic methods. Specifically, using interview transcripts 
and field notes, dominant trends were identified in each 
interview and then compared across the results of the 
other interviews to generate themes or patterns in the way 
participants described their CC-related experiences and 
symptoms. The way participants interpreted and responded 
to each of the draft PRO items during cognitive debriefing 
was summarized.
The iterative nature of the interview process, as well as 
the detailed analytic approach, ensured the achievement of 
concept saturation, defined by the FDA as “the point when 
no new relevant or important information emerges and col-
lecting additional data will not add to the understanding of 
how patients perceive the concept of interest.”20   Specifically, 
interviewing and analysis continued until no new symptoms 
were being identified.
Results
literature review
A total of 67 studies were identified that assessed patient-
reported symptoms of CC in the context of qualitative 
research, questionnaire validation, patient surveys, RCTs, 
and other interventional studies. Twelve studies identified 
and assessed patient-reported symptoms of CC for purposes 
other than testing the efficacy of a treatment, including 
two qualitative studies, three validation studies, and seven 
patient surveys; 41 studies were of RCTs and 14 studies 
were of interventions that were not placebo- or comparator-
controlled.
The CC symptoms that were reported (for example, in 
qualitative studies) or collected (in RCTs and other interven-
tional studies) in at least ten of the 67 studies reviewed are 
shown in Table 1. Regardless of the type of study reviewed, 
the CC symptoms most frequently reported or assessed Clinical and Experimental Gastroenterology 2014:7 submit your manuscript | www.dovepress.com
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included those symptoms addressed by the Rome Criteria (ie, 
BM frequency, stool consistency, straining, and incomplete 
evacuation). More than half of the studies also collected data 
on at least one abdominal symptom associated with CC (most 
frequently bloating), suggesting that these symptoms are 
recognized as potentially important to patients with CC. 
Patient interviews
Participants
Two iterative sets of in-person interviews were conducted, 
as described in the Methods section. Table 2 summarizes the 
participants’ demographic information, aggregated across the 
two rounds of interviews.
Concept elicitation
Participants spontaneously reported 62 potentially distinct 
concepts, including 12 bowel symptoms, 21 abdominal symp-
toms, and 29 consequences or impacts of CC. Although par-
ticipants described a larger number of abdominal symptoms, 
these symptoms were highly related to each other, often to 
the point of redundancy, and differences were often difficult 
for participants to articulate. Table 3 presents a complete 
list of the bowel and abdominal symptoms spontaneously 
reported or endorsed by at least two participants in response 
to directed probing. Four additional bowel symptoms (for 
example, changes in stool color, mucus in stool) and eleven 
additional abdominal symptoms (for example, knots in 
belly, tender stomach) were each reported by only one of 
the 28 participants.
Most participants spontaneously reported that they 
experienced infrequent, incomplete, and effortful BMs. In 
comparison to the abdominal symptoms, the bowel symp-
toms were consistently described by participants as unique 
and distinct from one another. For example, straining was 
consistently described as the act of “pushing” with excessive 
“force” during attempts to pass stool, whereas incomplete 
evacuation was described as the feeling that an insufficient 
Table 1 CC symptoms reported in at least ten of the 67 studies 
reviewed
CC symptom N of studies 
(N=67)
BM frequencya 67 (100%)
stool consistency/hard, lumpy stoolsa 56 (83.6%)
straininga 54 (80.6%)
incomplete evacuationa 39 (58.2%)
Bloating 36 (53.7%)
abdominal pain 28 (41.8%)
abdominal discomfort 24 (35.8%)
Gas 13 (19.4%)
Unsuccessful attempts to have a BM 13 (19.4%)
Note: asymptoms included in the rome Criteria for CC.
Abbreviations: CC, chronic constipation; n, number; BM, bowel movement.
Table 2 Demographic characteristics of interview participants
Demographic information N=28
sex
  Female 24 (85.7%)
  Male 4 (14.3%)
  age, years, average (range) 44.9 (19–74)
race
  White 19 (67.9%)
  african american/black 9 (32.1%)
Educationa
  high school 5 (17.9%)
  some college or 2-year degree 11 (39.3%)
  College graduate 12 (42.9%)
Note: aDoes not equal 100% due to rounding.
Abbreviation: n, number.
Table 3 symptoms reported by two or more participants (n=28)
Symptom Reported  
spontaneously
Reported  
when  
probed
Total  
number of   
reports
Bowel symptoms
  infrequent BMs 28 0 28 (100.0%)
  incomplete BMs 13 15 28 (100.0%)
  straining 20 8 28 (100.0%)
  hard (or lumpy) stool 22 5 27 (96.4%)
    Unsuccessful attempts  
to have a BM
18 3 21 (75.0%)
    stools too small  
(or too large)
18 2 20 (71.4%)
    long duration of  
bathroom visits
8 – 8 (28.6%)
  Digital manipulation 4 – 4 (14.3%)
abdominal symptoms
  abdominal pain 22 6 28 (100.0%)
  abdominal discomfort 15 13 28 (100.0%)
  Bloating 22 5 27 (96.4%)
  Gas 11 10 21 (75.0%)
  Trapped gas 11 5 16 (57.1%)
  Flatulence 7 5 12 (42.9%)
  Gas pain 6 6 12 (42.9%)
  strong odor of gas 2 – 2 (7.1%)
  Burping/belching 2 – 2 (7.1%)
  Feeling of fullness 13 7 20 (71.4%)
  abdominal cramping 13 5 18 (64.3%)
    stomach pain/ 
stomachache
14 4 18 (64.3%)
  Feeling backed up 12 – 12 (42.9%)
    Pain in sides or on  
one side
3 – 3 (10.7%)
  stomach upset 2 – 2 (7.1%)
Abbreviations: n, number; BM, bowel movement.Clinical and Experimental Gastroenterology 2014:7 submit your manuscript | www.dovepress.com
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amount of stool had been passed (for example, “you haven’t 
finished”). 
Although participants used a variety of terms to describe 
the abdominal symptoms associated with CC, the major-
ity that were reported spontaneously were either deemed 
equivalent to, or highly related to, one of three core concepts: 
abdominal pain; abdominal discomfort; and bloating. As seen 
in Table 3, abdominal pain and abdominal discomfort were 
the most commonly reported symptoms, closely followed 
by bloating; specifically, abdominal pain and abdominal 
discomfort were reported by all participants, and bloating 
was reported by all but one participant.
Abdominal pain was frequently described as a “sharp” 
or acute symptom (for example, “like a jab with a knife”); 
abdominal cramping and gas pain were commonly reported 
as specific types of abdominal pain. Commonly considered 
a lesser form of abdominal pain, abdominal discomfort was 
often described as a more chronic “dull”, “achy” symptom 
linked to other symptoms such as bloating, trapped gas, and 
feelings of fullness. Participants also commonly mentioned 
that abdominal pain was impossible to ignore (for example, 
“Pain would be where it grabs you or you feel like, ‘Oh I can’t 
move, it hurts too bad to move.’”), whereas they could still 
function with abdominal discomfort (for example, “Discom-
fort is, you know, you can walk around, but you know it’s there 
… you can go on”). These descriptions suggest that, while 
clearly related, abdominal pain and abdominal discomfort 
are distinct symptoms of CC.
Participants consistently described bloating as having 
two key components and a close relationship with trapped 
gas. The first component was abdominal distention, which 
was described as looking “huge … about to pop”, and 
“about 6-months pregnant”. Distention altered partici-
pants’ physical appearance and affected the clothes they 
were able to wear. The second component was a physical 
feeling, commonly described as a feeling of fullness and 
a source of abdominal discomfort (for example, “full and 
uncomfortable”, “there’s always this uncomfortable feeling 
that’s building up”).
Various manifestations of gas were mentioned by inter-
view participants ranging in intensity from trapped gas, 
which caused bloating and abdominal discomfort, to gas pain, 
a specific type of abdominal pain. One participant described a 
sequential relationship among these symptoms: “Gas causes 
you to get bloated [...] which causes you to have discomfort 
in your stomach.” While embarrassing at times, passing gas 
was linked to a sense of relief or to a reduction in bloating 
and discomfort.
While participants who reported a feeling of fullness 
typically associated this feeling with bloating, some also 
described a sensation of fullness as a feeling of being 
  completely full, as after a big meal (ie, “stuffed”). For exam-
ple, one participant noted, “It means that, ah, the capacity of 
your stomach is full and you, ah, you feel full. But you can’t 
void. You can’t let it out. So you feel full.”
While many participants spontaneously reported stom-
ach pains or stomachaches (number [n]=14) and abdomi-
nal cramping (n=13), these symptoms were either highly 
related to or completely redundant with the   symptoms 
of abdominal pain and/or abdominal discomfort. For 
example, abdominal cramping was described as a specific 
type of abdominal pain, which often signaled that a BM 
was imminent.
In addition to the bowel and abdominal symptoms, 
participants reported 25 additional physical complaints 
and four mental or emotional issues that were generally 
regarded by participants as the consequences of severe 
constipation (commonly defined as many days without a 
BM). For example, participants reported rectal pain, rec-
tal bleeding, and hemorrhoids as secondary to straining 
and hard stools. Participants also reported experiencing 
gastrointestinal problems, such as nausea and early satiety, 
and non-gastrointestinal issues, such as headaches, fatigue, 
and irritability, only after a prolonged period of time with-
out a BM. Table 4 presents the 16 concepts that at least two 
Table 4   Consequences  of  chronic  constipation  symptoms   
repo  rted by two or more participants (n=28)
Concept Total number   
of reports
rectal consequences
  rectal pain 15 (53.6%)
  hemorrhoids 12 (42.9%)
  rectal bleeding 11 (39.3%)
  rectal tearing 7 (25.0%)
  rectal burning 3 (10.7%)
Other consequences or impacts
  Moodiness, irritability 9 (32.1%)
  loss of appetite/early satiety 7 (25.0%)
  Back pain, backache 7 (25.0%)
  headaches 6 (21.4%)
  nausea 5 (17.9%)
  heartburn, indigestion 5 (17.9%)
  Fatigue, tiredness, low energy, lethargy 5 (17.9%)
    Chest pain (due to gas pressure or feeling of  
fullness in chest)
4 (14.3%)
  Feel “blah”, feel “miserable”, does not feel good 4 (14.3%)
  skin issues (for example, acne, skin not as supple) 3 (10.7%)
  Weight gain, feel heavier 2 (7.1%)
Abbreviation: n, number.Clinical and Experimental Gastroenterology 2014:7 submit your manuscript | www.dovepress.com
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participants reported as consequences of severe constipation. 
An additional 13 concepts were each reported by only one 
of the 28 participants.
structured questions related to symptom  
bother and importance
When asked to report their most bothersome CC symptoms, 
participants’ most frequent responses were the abdominal 
symptoms of pain and/or discomfort (n=10), and bloat-
ing (n=8). These abdominal symptoms were closely fol-
lowed by the bowel symptoms of infrequent or incomplete 
BMs (n=7).
Participants generally rated both their bowel and abdomi-
nal symptoms as very important. These data are summarized 
in Table 5.
When asked to select the five symptoms they would most 
like to see improve with treatment, the bowel symptoms of 
incomplete BMs, straining, and unsuccessful BMs, as well 
as the abdominal symptom of bloating, were most commonly 
mentioned by round 2 participants. In addition, all but two 
participants included at least one abdominal symptom in 
their “top-five” symptoms that are most important to treat. 
The results of these queries are further illustrated in Figure 1 
“Round 2 participant reports of the five most important CC 
symptoms to treat” (N=13).
Cognitive debriefing
Interview participants easily understood and answered each of 
the symptom severity items that were tested. Specifically, the 
majority of participants reported that the abdominal symp-
toms assessed (ie, abdominal pain, abdominal discomfort, 
and bloating) encompassed all of the abdominal symptoms 
that were important to them. The majority of the interview 
participants also reported that each of the abdominal symp-
toms tested was distinct and warranted individual assessment. 
When probed if any important abdominal symptoms were 
missing, only those symptoms described as the impacts of 
severe constipation (for example, nausea) were reported.
Discussion
The primary goal of this study was to identify those symp-
toms of CC that are of sufficient importance to patients to 
warrant assessment in CC clinical trials. Both the literature 
review and patient interview results indicate that abdominal 
symptoms associated with CC are equal in relevance to bowel 
symptoms, even though they are addressed at present less 
consistently in CC clinical trials. 
Qualitative interview results clearly demonstrated the 
importance of the following bowel and abdominal symptoms 
to CC patients: stool frequency; stool consistency; straining; 
incomplete evacuation; abdominal discomfort; bloating; and 
abdominal pain. Patients consistently reported that these 
symptoms were bothersome and important to treat, both 
within and across two separate sets of interviews conducted 
in two locations. Furthermore, patients indicated that reduc-
tions in the severity of these symptoms would constitute an 
improvement in their CC overall.
As there is no pathognomonic, laboratory, endoscopic, or 
other specific tool for the diagnosis of CC, both the diagnosis 
of this condition and its distinction from IBS-C are based on 
a set of symptom criteria, most often referable to the Rome 
Criteria. Constipation and its components (for example, infre-
quent BMs, hard or lumpy stools) are prominent features of 
both IBS-C and CC. While abdominal symptoms are present 
in both of these disorders, abdominal pain or discomfort that 
is either relieved following defecation or associated with a 
change in stool frequency/consistency, is a hallmark symp-
tom and diagnostic criterion of IBS-C alone. As previously 
noted, the Rome II Criteria12 were used by referring gastro-
enterologists to identify patients for interview participation. 
Although rigorous separation of the two populations is not 
possible based on the qualitative data collected in this study, 
the results suggest that there may be greater overlap between 
these two conditions than previously considered.
The FDA’s PRO guidance stresses that instrument develop-
ment should be based on extensive input from patients, and all 
concepts encompassed by a label claim must be measured to 
adequately support that claim.20 For example, if a PRO instru-
ment is developed to support a claim pertaining to reductions 
in symptom severity, the severity of all symptoms important 
to patients with that disease should be measured. Further, the 
FDA identified concept saturation as a criterion for determin-
ing whether qualitative data provided by patients are sufficient 
to demonstrate a PRO measure’s content validity.20 
Table 5 summary of importance ratingsa for core symptoms
Symptom Mean Median Range
BM completeness 3.0 3.0 2.5–3.0
abdominal discomfort 2.9 3.0 2.0–3.0
BM frequency 2.8 3.0 2.0–3.0
straining 2.7 3.0 1.0–3.0
Bloating 2.7 3.0 2.0–3.0
stool consistency 2.7 3.0 1.0–3.0
abdominal pain 2.4 3.0 0.0–3.0
Notes:  aimportance ratings: 0=	totally irrelevant; 1=	relevant but not important; 
2=	moderately important; 3=	very important.
Abbreviation: BM, bowel movement.Clinical and Experimental Gastroenterology 2014:7 submit your manuscript | www.dovepress.com
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Historically, the assessment of treatment response in CC 
clinical trials has focused primarily on bowel symptoms, 
despite awareness that both bowel and abdominal symptoms 
are prevalent among patients with CC. In addition, none of 
the measures used to assess CC symptom severity in currently 
conducted clinical trials meets the requirements described in 
the FDA’s PRO guidance. Specifically, these measures were 
not developed with patient input, and there is no evidence to 
demonstrate that these measures address all CC symptoms 
that are important to patients; furthermore, they do not dem-
onstrate that saturation was achieved.
The results of this study provide a strong foundation for 
the measurement of CC symptom severity in future clinical 
trials. While the sample sizes are relatively small, they are 
consistent with the standards for qualitative data collection, 
as recommended by the FDA,20 and as further articulated 
in practices advocated by the International Society for 
  Pharmacoeconomics and Outcomes Research.21   Specifically, 
the study inclusion and exclusion criteria ensured that inter-
view participants were similar to those who participate in CC 
clinical trials, the semistructured interview guide facilitated 
consistent data collection across interviews, and the interview 
guide used open-ended questions and scripted follow-up 
prompts to reduce opportunities for bias. Furthermore, inter-
viewing and analysis continued until the FDA’s criterion for 
concept saturation was satisfied.
The literature review and patient interviews produced 
mutually supporting results, providing converging evidence 
for their generalizability. Taken together, these results 
  provide strong evidence that the measurement of both 
bowel and abdominal symptoms in CC clinical trials is 
necessary to ensure a comprehensive assessment of treat-
ment response.
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Figure 1 Round 2 participant reports of the five most important CC symptoms to treat.
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